CanadaOmega Laboratories Limited Cisatracurium Besylate Injection USP Multidose (Cisatracurium 2 mg/mL), DIN 02408813, lots B5C646A and B5D664A is affected. The lots were recalled because the level of the degradation product benzaldehyde may be out of specification. Verify whether your product is one of the affected lots, consult your healthcare provider before discontinuing use, contact the recalling firm with questions, and report any side effects or other safety complaints to Health Canada.
What's being recalled
Depth of recall: Retailers
Companies: Juno Pharma Canada Inc., (Omega Laboratories Limited), 11177 Rue Hamon, Montreal, QC, Canada H3M 3E4.
How to identify it
Brand: Omega Laboratories Limited; Product Name: Cisatracurium Besylate Injection USP Multidose; Market Authorization: DIN 02408813; Dosage Form: Solution; Strength: Cisatracurium (Cisatracurium besilate) 2 mg/mL; Lot Number: B5C646A, B5D664A
The hazard
The level of the degradation product Benzaldehyde may be out of specification in the affected lots.
What to do
Verify if your product is affected.
Consult your healthcare provider prior to discontinuing use of the affected product(s), or for any health concerns.
Contact the recalling firm if you have any questions about the recall.
Report any health product related side effects to Health Canada.
Report any other health product safety complaints to Health Canada.
The official notice
This page is a summary of the notice published by Health Canada, collected from Health Canada, CFIA and Transport Canada. Check the original before you act on it.
Read the official notice (opens in a new tab)